ISI Articles | CenterWatch News Online

ISI

1 2 3 4 5

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

More... »

Isis to receive $14 million from Pfizer's Excaliard acquisition

Tuesday, November 22, 2011 11:12 AM

Isis Pharmaceuticals will receive up to $14 million from Pfizer for its equity ownership of Excaliard Pharmaceuticals from Pfizer's acquisition of Excaliard. Upon closing of the acquisition, Isis will receive an initial $4.4 million. Contingent payments of up to an additional $9.6 million could be paid to Isis upon achievement of various milestones associated with the clinical and commercial progress of EXC 001. Isis will continue to be eligible for milestone and royalty payments under its licensing agreement with Excaliard for EXC 001.

More... »

Foundation Fighting Blindness invests $8.25 million in gene therapy research

Wednesday, November 2, 2011 09:43 AM

The Foundation Fighting Blindness, a national nonprofit dedicated to advancing sight-saving research, has reported an $8.25 million investment in six new gene therapy research projects that are targeted to have treatments ready for clinical trials within three years. The grants focus on treating a broad range of retinal degenerative diseases and will be allocated through the Foundation's Translational Research Acceleration Program, which funds research efforts with strong, near-term clinical potential.

More... »

The CenterWatch Monthly, October 2011

Tuesday, October 4, 2011 11:01 AM

Sponsors take action to reduce protocol amendments

More... »

Physicians wary of using biosimilars

Wednesday, August 24, 2011 01:58 PM

Decision Resources finds that the majority of U.S. and European physicians are wary of using a biosimilar for an indication for which supporting clinical data are lacking. According to new analysis, physician attitudes about indication extrapolation-where a biosimilar needs only to show similarity in a phase III study for one indication, and it will be granted approval for other indications for which the branded product is used-vary by country. French physicians are the most conservative when asked about indication extrapolation when compared to German and U.S. physicians.

More... »

DecisionView to launch enrollment-centric metrics

Monday, August 15, 2011 08:00 AM

Clinical trial enrollment-focused software maker DecisionView is launching what it says will be the first benchmarking effort to focus tightly on enrollment metrics.

More... »

Quest, Genomic collaborate

Friday, July 15, 2011 10:25 AM

Quest Diagnostics and Genomic Vision announced a multi-year exclusive collaboration involving Genomic Vision's proprietary molecular combing genomic-analysis technology.

More... »

InSite Vision raises $22.2 million

Thursday, July 14, 2011 12:28 PM

InSite Vision has entered into a private placement financing transaction of approximately $22.2 million in exchange for the issuance of approximately 37 million shares of InSite Vision common stock and warrants to purchase approximately 14.8 million shares of InSite Vision common stock.

More... »

Vycor names head of strategic advisory board

Monday, July 11, 2011 12:51 PM

Vycor Medical has named Alvaro Pascual-Leone, M.D., Ph.D., head of the strategic advisory board of its NovaVision subsidiary.

More... »

Report: Clinical trials market growing rapidly

Tuesday, July 5, 2011 12:16 PM

A report by London-based visiongain predicts worldwide clinical trial services revenues will reach $32.73 billion in 2015. Revenues for CROs totaled $21.69 billion in 2010, according to Pharma Clinical Trial Services: World Market 2011-2021.

More... »

1 2 3 4 5